论文部分内容阅读
目的观察门冬胰岛素30治疗初诊2型糖尿病的临床疗效及安全性。方法回顾性分析本科室2012年4月至2013年8月期间收治的50例初诊2型糖尿病住院患者,根据患者当时接受的治疗方法,分成门冬胰岛素30治疗组(n=24),方案为每日3次皮下注射;人胰岛素治疗组(n=26)(方案为三餐前半小时注射短效人胰岛素诺和灵R,睡前注射中效人胰岛素诺和灵N),强化治疗2周后,观察两组患者空腹血糖(FBG)、餐后2小时血糖(2hBG)、睡前血糖控制情况及低血糖发生情况。结果分(1)两组患者相对于治疗前,8个时点的血糖均明显下降(P<0.01),门冬胰岛素30组较人胰岛素组控制更好,但差异无统计学意义(P>O.05);(2)门冬胰岛素30组低血糖发生率明显低于人胰岛素组(P<0.05),无严重低血糖及夜间低血糖事件;(3)门冬胰岛素30组患者满意度明显高于人胰岛素组。结论门冬胰岛素30不仅能有效降低初诊2型糖尿病患者的高血糖,尤其是餐后血糖,而且低血糖发生率低,患者满意度高。对于初诊的2型糖尿病患者,门冬胰岛素30每日三次强化治疗是个很好的选择。
Objective To observe the clinical efficacy and safety of insulin aspart 30 in newly diagnosed type 2 diabetic patients. Methods A retrospective analysis of 50 inpatients with newly diagnosed type 2 diabetes mellitus admitted during the period from April 2012 to August 2013 in our department was divided into 30 groups of aspart insulin (n = 24) according to the patients’ 3 times daily subcutaneous injection; human insulin treatment group (n = 26) (program for half an hour before the three meals a day injection of short-acting human insulin Novolin R, prenatal injection of midazolam neutral insulin N), intensive treatment for 2 weeks After fasting blood glucose (FBG), 2 hours postprandial blood glucose (2hBG), control of blood glucose before going to bed and hypoglycemia were observed. Results (1) Compared with pre-treatment and post-treatment, the blood glucose of the two groups were significantly decreased (P <0.01), insulin aspart 30 was better controlled than the human insulin group, but the difference was not statistically significant (P> 0.05); (2) The incidence of hypoglycemia in insulin aspart 30 group was significantly lower than that of human insulin group (P <0.05), no severe hypoglycemia and nocturnal hypoglycemia; (3) Obviously higher than the human insulin group. Conclusion Aspart insulin 30 not only can effectively reduce the high blood sugar in newly diagnosed type 2 diabetic patients, especially postprandial blood glucose, but also has a low incidence of hypoglycemia and high patient satisfaction. For patients with newly diagnosed type 2 diabetes, insulin aspart 30 is an excellent choice for intensive treatment three times daily.